We used a new tactile sensor to measure the elastic properties of skin in patients with systemic sclerosis or Raynaud's phenomenon. The sensor consists of a piezoelectric vibrator with vibration pickup to measure frequency changes when the sensor is placed on the skin. The mean frequency change at the skin surface of the proximal third phalanx in patients with systemic sclerosis was significantly lower than in age-and sexmatched controls. The results in systemic sclerosis patients were statistically correlated to the Modified Rodnan Skin Thickness Score. This technique was also used to measure the therapeutic efficacy of salpogrelate, a new specific serotonin receptor antagonist. A greater mean frequency change was seen after treatment. We conclude that this new tactile sensor is useful for quantitatively measuring skin sclerosis and may help determine the efficacy of therapeutic treatments.
Introduction
A number of studies have been published on the use of instruments for investigating the elastic properties of human skin, 1 -6 and such instruments have facilitated many advances in the fields of dermatology and cosmetic science. In general, the ground substance in skin 7 shows thixotropic behaviour, that is it shows a reduction in viscosity as shear stress increases, and the decreased viscosity is recovered slowly on standing. For example, Finlay, 8 using a rotary displacement servo system, showed that human skin contains a thixotropic ground substance that enables gliding of the outer surface in a complex pattern. The viscoelastic and complex biomechanical structure of skin necessitates the use of simplified mechanical models to measure and assess its biomechanical properties. 9 Developing a tactile sensor and measuring system allowed detection of the stiffness-and elasticity-related properties of human skin. 10 The sensor is based on a piezoelectric element and can measure displacement. In addition, it is hand-held and designed for easy and convenient use.
In patients with systemic sclerosis (SSc) the biomechanical properties of skin, such as elasticity and extensibility, are altered by fibrosis. We investigated whether this new tactile sensor is a useful tool for measuring skin hardness in patients with SSc, Raynaud's phenomenon or mixed connective tissue disease (MCTD; patients with MCTD usually have scleroderma and Raynaud's disease). The results were compared with those of the gold standard Modified Rodnan Skin Thickness Score (MRSTS). In addition, we investigated the use of the tactile sensor to measure the efficacy of salpogrelate treatment.
Patients and methods

PATIENTS
Systemic sclerosis patients who fulfilled the American
College of Rheumatology (formerly the American Rheumatism Association) classification criteria 11 and patients with Raynaud's phenomenon diagnosed on the basis of characteristic triphasic digital colour changes 12 were included in the study. The SSc patients had suffered from diffuse atrophic or sclerotic skin changes for at least 5 years. Confirmation of the diagnosis of SSc was obtained from a forearm skin biopsy. Patients with MCTD were also investigated and the diagnosis was based on a high serum titre of anti-U1 ribonuclease-sensitive extractable nuclear antigen antibodies. The clinical features of MCTD were an overlap of diffuse connective tissue diseases (systemic lupus erythematosus, SSc and polymyositis).
Age-and sex-matched controls were also recruited; these included patients with other autoimmune diseases (except for MCTD) and healthy individuals without Raynaud's phenomenon.
Those enrolled in the study had no other skin disorders, did not use vibrating tools, and did not participate in any sport that affected the skin on their fingers. Informed consent was obtained from all the participants, but ethical approval was not sought.
THE TACTILE SENSOR
The tactile sensor consists of a piezoelectric vibrator (61 kHz) with vibration pickup to measure the change in frequency when the sensor is placed on the skin; it is connected to a computer equipped with the appropriate software. Integrated with the tactile sensor is a displacement sensor that shows the spring compression loading when the sensor element is placed against the skin during measurement. Under certain conditions (e.g. fixed contact pressure), the change in frequency reflects the acoustic impedance of the object and is related to the stiffness of the soft tissue.
MEASUREMENT OF SKIN HARDNESS
Briefly, the measurements were made with the tactile sensor oscillating at a resonance frequency of about 61 kHz. It was set to measure the change in resonance frequency (∆F). ∆F = f x -f 0 , where f x is the resonance frequency of the sensor placed on the skin and f 0 is the non-contact frequency (61 kHz). A total of 150 measurements were made in sequence. To compare the degree of skin sclerosis quantitatively, the mean ∆F value between the 100th and 110th detection points, when the measurement became stable, was used.
Since the contact area of the sensor tip depends on the contact pressure, the resonance frequency of the piezoelectric element also changes according to how hard the sensor tip is pressed against the surface of the skin. The contact pressure of the sensor element was held constant by the spring. The compression of the spring when the sensor probe touched the skin (and thus the movement of the sensor element) was continually measured by the displacement transducer.
The ∆F was measured at the skin surface of the proximal third phalanx. The mean ∆F was also measured at the locations assessed when calculating the MRSTS. 13 -15 
MODIFIED RODNAN SKIN THICKNESS SCORE
The MRSTS was assessed by clinical palpation at multiple locations, assigning a score of 0 -3 to each site (0, normal; 1, thickened; 2, thickened, unable to pinch; 3, thickened, unable to move). 13 -15 
MEASUREMENT OF TREATMENT EFFICACY
The change in ∆F was measured in patients with autoimmune Raynaud's phenomenon, SSc or MCTD after administering the serotonin (5-hydroxytryptamine) receptor antagonist salpogrelate 16 at a dose of 300 mg/day for 4 weeks. Measurements were taken in the same way as described in the section on measuring skin hardness before and after salpogrelate therapy.
Salpogrelate therapy is used routinely in the clinic as therapy for these conditions.
STATISTICAL ANALYSIS
Results are given as the mean ± SD. Student's t-and F-tests were used for statistical comparison. A P-value < 0.05 was considered statistically significant. Statistical calculations were performed using the statistical software package STATVIEW II (Abacus Concepts, Inc., Berkeley, CA, USA).
Results
Five patients with SSc, 13 with Raynaud's phenomenon without SSc and MCTD, and five patients with MCTD were recruited to the study. There were a total of 23 age-and sexmatched controls, all of whom were female and ranged in age from 44 years to 66 years (mean ± SD 47.1 ± 15.8 years). The control women comprising six patients with systemic lupus erythematosus, three with Sjögren's syndrome, three with anti-phospholipid antibody syndrome, four with rheumatoid arthritis, two with Behçet's disease and five healthy individuals without Raynaud's phenomenon.
SKIN HARDNESS
The mean ∆F at the skin surface of the proximal third phalanx in patients with either atrophic or sclerotic SSc was significantly lower than in the age-and sex-matched controls ( Table 1 ). The mean ∆F values at the locations used to calculate the MRSTS are shown in Table 2 . MRSTS values were calculated for four patients, three with and one without SSc.
CORRELATION BETWEEN TACTILE SENSOR MEASUREMENTS AND MRSTS
To investigate the relationship between our measurements of skin hardness (using the tactile sensor) and the MRSTS, comparisons were made between MRSTS and mean ∆F values. Initial experiments demonstrated that the mean ∆F values associated with an MRSTS of 2 or 3 were statistically different from those associated with an MRSTS of 0 (P < 0.001). The mean ∆F value associated with an MRSTS of 1, however, was not statistically different from that associated with an MRSTS of 0 ( Fig. 1) .
MEASURING TREATMENT EFFICACY
We tested whether or not the sensor is useful for measuring treatment efficacy. The changes in ∆F measured after treating nine Table 3 .
In patient R2K, who suffered from unclassified connective tissue disease, ∆F was improved more (from 2040 to 2418) when treated with prostaglandin ointment and salpogrelate than with salpogrelate alone. In patient R6N who suffered from SLE, ∆F was not changed after taking low dose prednisone (from 1875 to 1822), but improved after taking salpogrelate and prednisolone (from 1822 to 2286). In this pilot study, salpogrelate improved the ∆F in the patients tested.
Discussion
There are several scores that use pinching to measure skin thickness, including the MRSTS, which is currently the gold standard. This test has been proven to be reasonably reliable, 14, 17, 18 but inexperienced general physicians may find it difficult to use. We report here a novel, non-invasive tactile sensor 19 that assesses physical properties such as stiffness and inverse compliance by measuring the change in resonance frequency when a vibrating ceramic rod touches the surface of an object. Preliminary results on measuring the physical properties of living tissue such as skin have given promising results. 20, 21 It has been evaluated both in a standardized silicone gum model and in a rat testis model, and was compared with an impression method that measures interstitial pressure and water displacement in skin. 22 The two methods correlated well, and the tactile sensor was able to detect differences that correlated with silicone stiffness as measured by an international standard (DIN ISO 2137, 150 g hollow cone). We have further developed this tactile sensor and measuring system to detect the stiffnessand elasticity-related properties of human skin. The sensor is hand-held and designed for easy and convenient use. Experimental results on silicone gum and in healthy Japanese and Swedish women indicated that the instrument was able to detect changes in the stiffness-and elasticity-related properties of human skin related to age, day-to-day variations and the application of cosmetics. 10 In the atrophic phase an SSc patient's skin becomes sclerotic and, as a result, its elasticity and viscosity decrease. When we used this new tactile sensor to quantitatively measure sclerosis of the skin, it was shown to be very sensitive in detecting changes in skin properties in SSc patients. In addition, the results using this new method were statistically correlated to the gold standard MRSTS. We also found some decrease in ∆F in patients with autoimmune Raynaud's phenomenon. The reason for this was unclear, since histopathological data on the skin in these patients were not available. It has been suggested that autoimmune Raynaud's phenomenon may represent a pre-SSc state, 23 and that recurrent Raynaud's phenomenon results in fibrotic change in the small vessels. It is also possible that the tactile sensor might be influenced by the skin blood flow.
To investigate whether this new tactile sensor might be helpful in determining the efficacy of treatment, we used it to measure changes in the ∆F after treatment with 24 In contrast, another serotonin antagonist, ketanserin, failed to show efficacy compared with placebo in a North American trial. 25 Salpogrelate and ketanserin have been shown to produce similar effects on serotonin-induced platelet aggregation and DNA synthesis of aortic smooth muscle cells due to their antagonism of 5-hydroxytryptamine-2 receptors. 26, 27 Salpogrelate, however, does not exhibit an α 1 -adrenergic receptor blocking action, unlike ketanserin, 28 and it is possible that the biological responses and side-effects of salpogrelate and ketanserin are not the same.
Our study shows that this new tactile sensor might be useful for quantitatively measuring sclerosis of the skin and assessing therapy efficacy. Further experiments are necessary to determine the efficacy of the sensor in relation to various other pathological states. 
